An exploratory pharmacoscintigraphic single centre, open-label, crossover Phase 1 trial assessing CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinsons disease
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Paralysis
- Focus Adverse reactions
Most Recent Events
- 24 Jan 2024 New trial record